Incyte (MEX:INCY) Short Percentage of Float


MEX:INCY Incyte Corp MEX:INCY
84 GF Score
Price MXN1,676.03
GF Value MXN1,464.02
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MEX:INCY vs INSM, BNTX, ROIV: Short Percentage of Float Comparison

For the Biotechnology subindustry, Incyte's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incyte Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Incyte's Short Percentage of Float falls into.


MEX:INCY
84GF Score
Incyte Corp MEX:INCY
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN1,676.03 is trading 14.5% above its estimated GF Value™ of MXN1,464.02. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • Short Percentage of Float:
  • GF Value™: MXN1,464.02 vs. price of MXN1,676.03 (14.5% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score

Get the complete analysis for MEX:INCY

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,676.03
Price
MXN1,464.02
GF Value